Led the investment in TrialSpark at Felicis Ventures and followed the company across three fund vehicles (Felicis → Felicis → FPV) through three consecutive rounds over seven years; founding General Partner of Google Ventures; built Google Analytics and Google Voice; holds 17 U.S. patents; one of the few individual investors whose personal commitment to Formation Bio transcends any single fund.
Wesley Tien-Houi Chan (born 1978) is an American venture capitalist and the co-founder and managing partner of FPV Ventures. His family immigrated from Hong Kong to the United States in the 1970s, and Chan grew up in modest financial circumstances. As a teenager, he found a Craigslist job washing lab beakers at Caltech, where he impressed lab manager Ellen Rothenberg enough to earn her help getting admitted to MIT. He credits Rothenberg for everything that followed: “If it wasn’t for MIT, I wouldn’t have found Google. If it wasn’t for Google, I wouldn’t have found Google Ventures. If it wasn’t for Google Ventures, I wouldn’t have found my team at Felicis. And if it wasn’t for Felicis, I wouldn’t have had Canva and all these amazing companies, many of them run by immigrants or people that have lots of grit” [1] [2].
Chan earned his B.S. in Computer Science and Electrical Engineering from MIT and completed his Master’s of Engineering at the MIT Media Lab (2001). He also worked at HP Labs as a senior software engineer and at Microsoft Research as a research fellow before joining Google [3].
At Google, Chan built two products that became core infrastructure: Google Analytics (through the acquisitions of Urchin Software and MeasureMap) and Google Voice (through acquisitions of GrandCentral and Gizmo). He holds 17 U.S. patents for his foundational work creating Google AdWords. He received Google’s Founders Award — the company’s most prestigious recognition — for leading the development of Google’s early client efforts, which contributed to the creation of Google Chrome [4] [5].
Venture Capital Career
In 2009, Chan became one of the founding General Partners of Google Ventures (GV), where he built the seed investing program and focused on early-stage companies. At GV, he led investments in AngelList, Optimizely, Parse (acquired by Facebook), Gusto, Plaid, Robinhood, Vungle ($750M exit to Blackstone), and iPerian (acquired by Bristol-Myers Squibb). He sat on boards or held observer seats in many of these companies. In January 2014, he stepped down as a General Partner and became an entrepreneur-in-residence [6] [7].
In December 2014, Chan joined Felicis Ventures as Managing Director, co-managing the fund with fellow former Google employee Aydin Senkut. At Felicis, Chan invested in and served on the boards of multiple unicorns including Canva (where his board seat stake is reportedly worth north of $40 billion), Guild Education, Culture Amp, Checkr, Sourcegraph, Zipline, and Astranis. He also invested in a cluster of biotech companies including TrialSpark, Orca Bio, Whole Biome, ProteinQure, Juvena Therapeutics, Spring Discovery, and Overture Life [8] [9]. Business Insider named Chan to their Top 100 Seed Investors list for two consecutive years (2021, 2022), and Forbes named him to the Midas List of top venture capitalists in 2024 [10].
In 2022, Chan co-founded FPV Ventures with Pegah Ebrahimi (formerly the youngest CIO at Morgan Stanley, who also worked on Google’s IPO). FPV manages $450 million and focuses on backing “mission-driven founders” who are “underrepresented minorities or women.” Chan has been open about his identity as an openly LGBTQ+ venture capitalist: “There aren’t many of them, and there’s probably 6,000 venture capitalists. Why is there such low representation? And the number of openly out ones like us is even lower” [11] [12].
Over his career, Chan has invested in over 20 unicorns and five decacorns (Canva, Flexport, Guild Education, Plaid, Robinhood). He was the first check into most of them [13].
Formation Bio: Three Funds, Seven Years
Chan is explicitly documented as a TrialSpark investor. The Gold House profile lists “TrialSpark” among his led rounds at Felicis, and the Venture Unlocked podcast includes it among his unicorn investments [8] [9]. His involvement spans three distinct fund vehicles across three funding rounds:
| Round | Date | Fund Vehicle |
|---|---|---|
| Venture Round | October 2018 | Felicis Ventures |
| Series C | September 2021 | Felicis Ventures |
| Series D | June 2024 | FPV Ventures |
This cross-fund continuity is rare. When Chan left Felicis and co-founded FPV, he chose to reinvest in Formation Bio through his new vehicle — a decision that reflects personal conviction rather than institutional momentum. Thrive Capital (Kushner) and Sequoia Capital (Lin/Moritz) show comparable continuity, but those are single-firm positions. Chan’s commitment crosses firm boundaries, meaning his belief in the company’s trajectory is independent of any single fund’s thesis or incentive structure.
The Biotech Portfolio
TrialSpark/Formation Bio is not an outlier in Chan’s portfolio. He has a sustained biotech investment thesis spanning his Google Ventures, Felicis, and FPV careers:
| Company | Sector | Exit/Status |
|---|---|---|
| iPerian | Cell reprogramming | Acquired by Bristol-Myers Squibb |
| Orca Bio | Cell therapy | Active |
| Whole Biome | Microbiome therapeutics | Active |
| ProteinQure | AI protein engineering | Active |
| Juvena Therapeutics | Regenerative medicine | Active |
| Spring Discovery | AI drug discovery | Active |
| Overture Life | Reproductive technology | Active |
| TrialSpark/Formation Bio | Clinical trials / pharma acquisition | Active |
| The Climate Corporation | Agricultural biotech | Acquired by Monsanto |
The iPerian exit to Bristol-Myers Squibb is particularly relevant: it is a proof-of-concept for the exact business model Formation Bio now operates at scale. Acquire a biotech asset, develop it, sell to big pharma. Formation Bio’s Libertas Bio subsidiary executed the same play when it licensed gusacitinib to Sanofi for up to €545 million in June 2025. Chan’s investment thesis appears to include pharma acquisition plays as a deliberate category [6].
Network Connections
Google / Brin / 23andMe: Chan’s years at Google alongside founders Sergey Brin and Larry Page connect him to the broader investigation through a specific pathway. Brin was formerly married to Anne Wojcicki, who co-founded 23andMe. 23andMe partnered with TrialSpark in September 2019 for genetic data integration into clinical trial recruitment. Wojcicki later used the same nonprofit-wrapper playbook as OpenAI when she created TTAM Research Institute to rebuy 23andMe out of bankruptcy. Chan, Brin, Wojcicki, and TrialSpark all intersect through the Google alumni network [3].
MIT Nexus: Chan’s MIT background connects to the MIT touchpoints documented across the Altman network, including Tavneet Suri (MIT Sloan, OpenResearch advisory board). The MIT Media Lab, where Chan completed his master’s, has been a pipeline for both technology executives and AI researchers.
Pegah Ebrahimi / FPV: Chan’s co-founder at FPV was the youngest CIO at Morgan Stanley and worked on Google’s IPO. The Morgan Stanley connection potentially touches the financial infrastructure that supports OpenAI’s commercial operations and Formation Bio’s Series D fundraising [12].
Google Chrome / Founders Award: Chan received Google’s Founders Award for work that contributed to Google Chrome. Chrome is now the browser through which billions of people access ChatGPT, Google’s competing AI products, and the health-related searches that clinical trial recruitment (including Formation Bio’s Muse tool) targets.
Nodes / Open Questions
- Does Chan hold a board seat or observer rights at Formation Bio through any of his three fund vehicles?
- The biotech portfolio (iPerian, Orca Bio, Whole Biome, ProteinQure, Juvena, Spring Discovery, Overture Life, TrialSpark) represents a substantial cluster. Is pharma acquisition a stated thesis for FPV, or does Chan select these individually?
- Chan was at Google with Brin. Did Chan have any direct involvement with the 23andMe partnership that TrialSpark announced in September 2019?
- Aydin Senkut (Felicis co-manager with Chan) — does Senkut have any independent position in the Altman network or Formation Bio?
- FPV manages $450 million. What percentage of that fund is allocated to the Formation Bio Series D position?
- Chan’s 17 patents relate to advertising technology (AdWords). Formation Bio’s Muse tool does patient recruitment targeting through digital channels. Is there a methodology overlap between advertising-technology targeting and clinical-trial-patient targeting?
- Gold House recognized Chan as one of the 100 Most Impactful Asians of the Year (2021). Does Gold House have any organizational connection to other Altman network entities?
- Pegah Ebrahimi worked on Google’s IPO at Morgan Stanley. Does Morgan Stanley have any role in Formation Bio’s financial operations or the anticipated OpenAI IPO?
Sources
- [Archive] (https://techcrunch.com/2024/06/02/wesley-chan-venture-capital-unicorn)
- [Archive] (https://www.globalvillagespace.com/tech/how-wesley-chans-personal-journey-shaped-his-venture-capital-success/)
- [Archive] (https://en.wikipedia.org/wiki/Wesley_Chan)
- [Archive] (https://goldhouse.org/people/wesley-chan/)
- [Archive] (https://grokipedia.com/page/wesley_chan)
- [Archive] (https://techcrunch.com/?p=1104921)
- [Archive] (https://en.wikipedia.org/wiki/Wesley_Chan)
- [Archive] (https://goldhouse.org/people/wesley-chan/)
- [Archive] (https://ventureunlocked.substack.com/p/fpvs-wes-chan-the-path-to-backing)
- [Archive] (https://grokipedia.com/page/wesley_chan)
- [Archive] (https://citytelegraph.com/technology/166825/from-lab-beakers-to-unicorns/)
- [Archive] (https://citytelegraph.com/technology/166825/from-lab-beakers-to-unicorns/)
- [Archive] (https://techcrunch.com/2024/11/03/wesley-chan-on-what-he-looks-for-as-hes-shopping-for-potential-unicorns)